Full Text View
Tabular View
No Study Results Posted
Related Studies
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
This study has been completed.
Study NCT00001338   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: March 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasms
Fever
Hematologic Diseases
Neutropenia
Sepsis
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Agranulocytosis
Breast Diseases
Leukocyte Disorders
Leukopenia
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
FLAC chemotherapy with GM-CSF
Additional drug interventions recognized in this trial
Doxorubicin
Fluorouracil
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services